Skip to main content

Table 1 Specific adverse events reported by participants who received a full course (28 days) or a short course (5 days) of the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate, one pill, once a day, as post-exposure prophylaxis (PEP) for sexual exposure to HIV infection

From: Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis

  28 days PEP 5 days PEP
Total 218 (100.0)a 50 (100.0)
At least one adverse event 132 (60.6 [54.0–67.1]) 15 (30.0 [16.8–43.1])
Fatigue 57 (26.1 [20.3–32.0]) 5 (10.0 [1.4–18.6])
Abdominal disorders   
 - Nausea 55 (25.2 [19.4–31.0]) 6 (12.0 [2.7–21.3])
 - Vomiting 5 (2.3 [0.3–4.3]) 4 (8.0 [0.2–15.8])
 - Diarrhea 37 (17.0 [11.9–22.0]) 1 (2.0 [0–6.0])
 - Abdominal pain 18 (8.3 [4.6–11.9]) 0
 - Dysphagia 1 (0.5 [0–1.4]) 0
 - Dysgueusia 1 (0.5 [0–1.4]) 0
Headache 17 (7.8 [4.2–11.4]) 3 (6.0 [0–12.8])
Vertigo 5 (2.3 [0.3–4.3]) 0
Insomnia 3 (1.4 [0–2.9]) 0
Visual trouble 1 (0.5 [0–1.4]) 0
Arthralgia or myalgia 2 (0.9 [0–2.2]) 0
Fever sensation 3 (1.4 [0–2.9]) 0
Rash 2 (0.9 [0–2.2]) 0
Cytolysis 3 (1.4 [0–2.9]) 0
  1. Data are no. (%, 95% CI)
  2. aData on tolerability were missing for 16 participants who were prescribed 28 days of PEP and were lost to follow-up before the end of treatment